Pfizer at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Pfizer at ASHG 2026 in Montréal: 3 presentations (2 posters, 1 lightning talk).

Organization	ASHG 2026 Attendance
Pfizer Cambridge, Massachusetts	1 Associate Director, Translational Medicine Statistics · 1 Statistical Genetics Postdoc
pfizer.com\|LinkedIn Public company Pfizer develops and manufactures innovative medicines and vaccines for global healthcare markets. The FDA approved the Pfizer-BioNTech XFG-adapted COVID-19 vaccine, an updated formulation now available for the current season. › The FDA approved the Pfizer-BioNTech XFG-adapted COVID-19 vaccine, an updated formulation now available for the current season. 2026-08 · source The EMA validated Pfizer and Valneva's Lyme disease vaccine candidate application, moving it toward European approval. 2026-08 · source The European Commission authorized Pfizer and BioNTech's XFG-adapted COVID-19 vaccine across the EU. 2026-07 · source Source: company newsroom Q2 2026 revenue $15.0B, up 1% operationally › FY2026 revenue guidance raised by $500M at the midpoint, to $60.5B-$62.5B. · 2026-08-04 “Second-Quarter 2026 Revenues of $15.0 Billion, Representing 1% Year-over-Year Operational Growth Raises Full-Year 2026 Revenue Guidance(2) by $500 Million at the Midpoint to a Range of $60.5 to $62.5 Billion” Source: results release Currently hiring: 10 open roles › Source: careers page	Talk Wed Oct 21 1:51 pm Part of Decoding Genetic Risk Across Ancestry and Sex in Polygenic Disorders Proteomic signatures of lifestyle capture environmental risk and predict incidence of major chronic diseases independently of polygenic risk Room 511/Level 5 Collaborators: University of Pennsylvania, Kangwon National University +1 more ProteomicsComplex diseasesPrecision medicineRisk assessment Poster Thu Oct 22 4:15 pm ★ Reviewers’ Choice Part of Complex Traits and Polygenic Disorders Poster Thursday Session Proteomic signatures of lifestyle capture environmental risk and predict incidence of major chronic diseases independently of polygenic risk Exhibit & Poster Hall · Board 8303T Collaborators: University of Pennsylvania, Kangwon National University +1 more Complex diseasesObesityPrecision medicineProteomics Poster Fri Oct 23 2:30 pm Part of Statistical Genetics and Genetic Epidemiology Poster Friday Session Integrating AlphaMissense predictions and missense variant associations to scale human genetic target evaluation for drug discovery Exhibit & Poster Hall · Board 8416F Machine learningGenotype-phenotype correlationsExome/genome sequencingVariant interpretation

Organization

ASHG 2026 Attendance

Pfizer

Cambridge, Massachusetts

1 Associate Director, Translational Medicine Statistics · 1 Statistical Genetics Postdoc

pfizer.com|LinkedIn

Public company

Pfizer develops and manufactures innovative medicines and vaccines for global healthcare markets.

The FDA approved the Pfizer-BioNTech XFG-adapted COVID-19 vaccine, an updated formulation now available for the current season.

›

The FDA approved the Pfizer-BioNTech XFG-adapted COVID-19 vaccine, an updated formulation now available for the current season.

2026-08 · source

The EMA validated Pfizer and Valneva's Lyme disease vaccine candidate application, moving it toward European approval.

2026-08 · source

The European Commission authorized Pfizer and BioNTech's XFG-adapted COVID-19 vaccine across the EU.

2026-07 · source

Source: company newsroom

Q2 2026 revenue $15.0B, up 1% operationally

›

FY2026 revenue guidance raised by $500M at the midpoint, to $60.5B-$62.5B. · 2026-08-04

“Second-Quarter 2026 Revenues of $15.0 Billion, Representing 1% Year-over-Year Operational Growth Raises Full-Year 2026 Revenue Guidance(2) by $500 Million at the Midpoint to a Range of $60.5 to $62.5 Billion”

Source: results release

Currently hiring: 10 open roles

›

Source: careers page

Talk

Wed Oct 21
1:51 pm

Part of Decoding Genetic Risk Across Ancestry and Sex in Polygenic Disorders

Proteomic signatures of lifestyle capture environmental risk and predict incidence of major chronic diseases independently of polygenic risk

Room 511/Level 5

Collaborators: University of Pennsylvania, Kangwon National University +1 more

ProteomicsComplex diseasesPrecision medicineRisk assessment

Poster